Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.

Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.
复制标题

DOI:
10.1016/j.virol.2014.10.035
复制
发表时间:
2015-01-15
期刊:
影响因子:
3.7
通讯作者:
van den Pol, Anthony N.
van den Pol, Anthony N.
中科院分区:
医学3区
文献类型:
--
作者:
Wollmann, Guido;Paglino, Justin C.;Maloney, Patrick R.;Ahmadi, Sebastian A.;van den Pol, Anthony N.

文献摘要

参考文献

被引文献

相似文献

水疱性口炎病毒(VSV)作为疫苗载体和溶瘤病毒具有广阔的应用前景。然而,有关VSV神经毒性的报道仍然令人担忧。我们使用小鼠和人脑培养以及体内小鼠模型比较了12种抗病毒化合物控制VSV-CT9-M51和VSV-rp30感染的效果。利巴韦林和干扰素-α的抑制率、细胞毒性和感染性最强,霉酚酸、氯喹和腺嘌呤9-β-D-阿拉伯呋喃诺苷也有一定的抑制作用。为了产生持续的干扰素暴露,我们制作了一个表达小鼠干扰素的腺相关病毒载体;aav-m干扰素-β保护小鼠脑细胞免受VSV的侵袭,利巴韦林和氯喹的组合也是如此。脑内AAv-mIFN-β对VSV-CT9-M51有保护作用。在带有人脑胶质母细胞瘤的SCID小鼠中,aav-m干扰素-β适度提高了存活率。β后注射VSV-CT9-M51可使小鼠的中位生存期提高一倍;一些存活的小鼠肿瘤被完全摧毁。综上所述,这些数据表明,AAV-干扰素或干扰素与利巴韦林和氯喹联合使用可提供最佳的抗病毒组合,以对抗大脑中的VSV。
Vesicular stomatitis virus (VSV) shows promise as vaccine-vector and oncolytic virus. However, reports of neurotoxicity of VSV remain a concern. We compared 12 antiviral compounds to control infection of VSV-CT9-M51 and VSV-rp30 using murine and human brain cultures, and in vivo mouse models. Inhibition of replication, cytotoxicity and infectivity was strongest with ribavirin and IFN-α and to some extent with mycophenolic acid, chloroquine, and adenine 9-β-D-arabinofuranoside. To generate continuous IFN exposure, we made an adeno-associated virus vector expressing murine IFN; AAV-mIFN-β protected mouse brain cells from VSV, as did a combination of ribavirin and chloroquine. Intracranial AAV-mIFN-β protected the brain against VSV-CT9-M51. In SCID mice bearing human glioblastoma, AAV-mIFN-β moderately enhanced survival. VSV-CT9-M51 doubled median survival when administered after AAV-mIFN-β; some surviving mice showed complete tumor destruction. Together, these data suggest that AAV-IFN or IFN with ribavirin and chloroquine provide an optimal anti-virus combination against VSV in the brain.
DOI: 10.1128/jvi.37.3.1060-1065.1981
发表时间: 1981-01-01
影响因子: 5.4
作者:
COOMBS, K;MANN, E;BROWN, DT
通讯作者: BROWN, DT
DOI: 10.1016/j.virol.2006.10.026
发表时间: 2007-03-30
期刊: VIROLOGY
影响因子: 3.7
作者:
Johnson, J. Erik;Nasar, Farooq;Udem, Stephen A.
通讯作者: Udem, Stephen A.
DOI: 10.1016/j.patbio.2006.07.008
发表时间: 2006-12-01
影响因子: --
作者:
Jeulin, H.;Grancher, N.;Venard, V.
通讯作者: Venard, V.
DOI: 10.1073/pnas.0602460103
发表时间: 2006-05-16
影响因子: 11.1
作者:
Delhaye, Sophie;Paul, Sophie;Michiels, Thomas
通讯作者: Michiels, Thomas
DOI: 10.1016/j.ymthe.2005.02.017
发表时间: 2005-07-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Berraondo, P;Ochoa, L;Prieto, J
通讯作者: Prieto, J